First-line icotinib versus cisplatine/pemetrexed plus pemetrexed maintenance therapy in lung adenocarcinoma patients with sensitizing EGFR mutation (CONVINCE).

Yuankai Shi, Fenlai Tan, Baohui Han et al.|Journal of Clinical Oncology|2016

Cited by 14